Poor Biological Factors and Prognosis of Interval Breast Cancers: Long-Term Results of Bahçeşehir (Istanbul) Breast Cancer Screening Project in Turkey.

JCO Global Oncology
Neslihan CabioğluVahit Özmen

Abstract

The Turkish Bahçeşehir Breast Cancer Screening Project was a 10-year, organized, population-based screening program carried out in Bahçeşehir county, Istanbul. Our aim was to examine the biologic features and outcome of screen-detected and interval breast cancers during the 10-year study period. Between 2009 and 2019, 2-view mammograms were obtained at 2-year intervals for women aged 40 to 69 years. Clinicopathological characteristics including ER, PR, HER2-neu, and Ki-67 status were analyzed for those diagnosed with breast cancer. In 8,758 screened women, 131 breast cancers (1.5%) were detected. The majority of patients (82.3%) had prognostic stage 0-I disease. Contrarily, patients with interval cancers (n = 15; 11.4%) were more likely to have a worse prognostic stage (II-IV disease; odds ratio [OR], 3.59, 95% CI, 0.9 to 14.5) and high Ki-67 scores (OR, 3.14; 95% CI, 0.9 to 11.2). Interval cancers detected within 1 year were more likely to have a luminal B (57.1% v 31.9%) and triple-negative (14.3% v 1%) subtype and less likely to have a luminal A subtype (28.6% v 61.5%; P = .04). Patients with interval cancers had a poor outcome in 10-year disease-specific (DSS) and disease-free survival (DFS) compared with those with screen-...Continue Reading

References

Jan 26, 2000·British Journal of Cancer·R P GroenendijkT Wobbes
May 4, 2000·Journal of the National Cancer Institute·F D GillilandC R Key
Feb 13, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C FidanerD M Parkin
Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·T SørlieA L Børresen-Dale
Sep 2, 2004·JAMA : the Journal of the American Medical Association·Heikki JoensuuJohan Lundin
Aug 18, 2005·Journal of the National Cancer Institute·Yu ShenDonald A Berry
May 17, 2008·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Wenli DongYu Shen
Jul 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Harri SihtoHeikki Joensuu
Jul 11, 2009·BMJ : British Medical Journal·Karsten Juhl Jørgensen, Peter C Gøtzsche
Feb 26, 2011·Journal of the National Cancer Institute·Stella MookMarjanka K Schmidt
Sep 6, 2011·Breast Cancer Research and Treatment·Laura J EssermanLaura J van 't Veer
Dec 30, 2011·Breast Cancer Research : BCR·Tiina LehtimäkiJohan Lundin
Jan 26, 2012·European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)·Anna M ChiarelliUNKNOWN Breast Screening Study Group
Sep 11, 2012·Journal of Cancer Research and Clinical Oncology·A CaldarellaE Paci
Nov 3, 2012·Lancet·UNKNOWN Independent UK Panel on Breast Cancer Screening
Mar 20, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Arda KayhanVahit Ozmen
Oct 6, 2016·Diagnostic and Interventional Radiology : Official Journal of the Turkish Society of Radiology·Arda KayhanVahit Özmen
Jun 2, 2018·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Maria SalaUNKNOWN CAMISS Study Group
Jun 18, 2018·Journal of Cancer Research and Clinical Oncology·Claire M B HollowayPatti A Groome
Jul 15, 2018·Breast Cancer Research and Treatment·Katie M O'BrienLinda Sharp
Jul 18, 2019·European Journal of Breast Health·Vahit ÖzmenVolkan Doğru
Jan 15, 2020·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Nadine ZielonkeUNKNOWN EU-TOPIA consortium
Apr 30, 2020·Cancer·Ophira GinsburgBenjamin O Anderson
May 11, 2020·Value in Health Regional Issues·Popy YuniarRichard Norman

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
dissection

Software Mentioned

SPSS

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.